Terms of the deal have not been disclosed.

With offices in Leuven of Belgium and Boston of US, Cartagenia provides variant assessment support and lab report automation software, database systems and related services to genetic labs, pathology labs and clinicians.

Cartagenia CEO Herman Verrelst said: "Joining forces with Agilent is an excellent strategic fit and provides tremendous opportunity both for our customers-who will benefit from integration with a broad family of solutions and a range of new applications-and for our team, as we’ll be able to further accelerate our success and growth through Agilent’s global reach and leading footprint in clinical labs."

The Cartagenia Bench platform allows technicians, lab directors and clinicians to visualize, evaluate and report clinical genetics data in the context of patient information.

The platform helps labs to build an internal knowledge base, variant assessment SOPs, automate report drafting, as well as to access a wide range of community-validated, private and premium content resources, whether for oncology or inherited disease.

Agilent noted that Cartagenia’s solutions are FDA-registered as exempt class I medical devices in the US and as class I medical devices in Europe.

Subject to local laws and regulations and customary closing conditions, the deal is expected to be completed in this month.